Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23533422 | 0.80 | GPR84 (0.45) | MEN1KMT2A | |
| SCHEMBL11838734 | 0.80 | GPR84 (0.45) | MEN1KMT2A | |
| SCHEMBL11829345 | 0.80 | GPR84 (0.45) | MEN1KMT2A | |
| SCHEMBL23533333 | 0.77 | CA1 (0.42) | — | |
| SCHEMBL8787170 | 0.76 | — | — | |
| SCHEMBL9855168 | 0.75 | TSHR (0.41) | MEN1CYP1A2KMT2A | |
| SCHEMBL2807710 | 0.75 | TSHR (0.41) | — | |
| SCHEMBL244829 | 0.74 | TSHR (0.50) | MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL23533471 | 0.73 | TSHR (0.44) | MEN1CYP1A2KMT2A | |
| SCHEMBL8733717 | 0.73 | TSHR (0.48) | MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102256952-B | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI | 2013-12-11 | — | — | CN | disclosed |
| EP-2379517-B1 | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8314247-B2 | Hydrazone derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-11-20 | — | — | US | disclosed |
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| CN-102256952-A | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI | 2011-11-23 | — | — | CN | disclosed |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| EP-2105435-A1 | HYDRAZONE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1907387-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | SOAT1 1657/4885MEN1 4054/4885FAAH 4205/4885 |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | GCK, KHK, GCKR | SOAT1 1657/4885MEN1 4054/4885FAAH 4205/4885 |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | SOAT1 2054/4885MEN1 4564/4885FAAH 2736/4885 |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | GCK, GCKR, HK1 | SOAT1 2985/4885MEN1 3208/4885FAAH 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.